Cargando…

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival

Detalles Bibliográficos
Autores principales:	Vendramini, Elena, Bomben, Riccardo, Pozzo, Federico, Benedetti, Dania, Bittolo, Tamara, Rossi, Francesca Maria, Dal Bo, Michele, Rabe, Kari G., Pozzato, Gabriele, Zaja, Francesco, Chiarenza, Annalisa, Di Raimondo, Francesco, Braggio, Esteban, Parikh, Sameer A., Kay, Neil E., Shanafelt, Tait D., Del Poeta, Giovanni, Gattei, Valter, Zucchetto, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756038/ https://www.ncbi.nlm.nih.gov/pubmed/30872781 http://dx.doi.org/10.1038/s41375-019-0444-6

Ejemplares similares

KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
por: Vendramini, Elena, et al.
Publicado: (2022)

SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
por: Pozzo, Federico, et al.
Publicado: (2020)

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013)

P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
por: Pozzo, Federico, et al.
Publicado: (2023)

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells
por: Dal Bo, Michele, et al.
Publicado: (2015)

Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond
por: Pozzo, Federico, et al.
Publicado: (2022)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukemia
por: Del Poeta, Giovanni, et al.
Publicado: (2020)

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
por: Tissino, Erika, et al.
Publicado: (2018)

Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance
por: Zucchetto, Antonella, et al.
Publicado: (2006)

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
por: Cohen, Jared A., et al.
Publicado: (2020)

P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
por: Vit, Filippo, et al.
Publicado: (2023)

S143: NATURAL CLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH BIMODAL CD49D EXPRESSION REVEALS CD49D PLASTICITY
por: Tissino, Erika, et al.
Publicado: (2023)

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy
por: Cohen, Jared A., et al.
Publicado: (2020)

P597: XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING
por: Talotta, Donatella, et al.
Publicado: (2023)

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance
por: Dal-Bo, Michele, et al.
Publicado: (2009)

Integrin Signaling Shaping BTK-Inhibitor Resistance
por: Polcik, Laura, et al.
Publicado: (2022)

VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects
por: Härzschel, Andrea, et al.
Publicado: (2020)

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
por: Rossi, Francesca M, et al.
Publicado: (2010)

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21
por: Ganghammer, Sylvia, et al.
Publicado: (2015)

P608: THE EXPRESSION OF CYTOR LNCRNA HAS POOR PROGNOSTIC VALUE IN CLL PATIENTS AND IS ASSOCIATED WITH MICROENVIRONMENTAL STIMULI.
por: Hernández, Lluís, et al.
Publicado: (2023)

IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
por: Bulian, Pietro, et al.
Publicado: (2012)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
por: Yang, Tianyou, et al.
Publicado: (2019)

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer
por: Eshraghi, Abbas, et al.
Publicado: (2020)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential
por: Dal Bo, Michele, et al.
Publicado: (2015)

KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015
por: Jouini, Raja, et al.
Publicado: (2019)

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms
por: Hutterer, Evelyn, et al.
Publicado: (2015)

Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models
por: Capolla, Sara, et al.
Publicado: (2023)

KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan
por: Awidi, Muhammad, et al.
Publicado: (2019)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
por: Gökmen, İvo, et al.
Publicado: (2023)

Shorter mothers have shorter pregnancies
por: Derraik, José, et al.
Publicado: (2015)

A Career in Surgical Oncology: Finding Meaning, Balance, and Personal Satisfaction
por: Shanafelt, Tait
Publicado: (2007)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute
por: Kim, Yonggoo, et al.
Publicado: (2020)

Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer
por: OUNISSI, Donia, et al.
Publicado: (2021)

KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer
por: Saharti, Samah
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s4u7bhl0v17cmmgaq7i62k43jp